Trinh Tanya, Haridas Anjana S, Sullivan Timothy J
†Department of Surgery, University of Queensland; and ‡Department of Ophthalmology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Ophthalmic Plast Reconstr Surg. 2016 Nov/Dec;32(6):e128-e129. doi: 10.1097/IOP.0000000000000310.
Alemtuzumab (Campath-1H) is a humanized anti-CD52 monoclonal antibody used in the treatment of multiple sclerosis (MS). Studies demonstrate significant reduction in relapse risk and the risk of accumulating sustained disability. Adverse events include infusion-associated reactions, infections, and secondary autoimmunity. Systemic thyroid disease is the most common secondary autoimmune event and affects up to approximately 30% of treated patients. This is the first description of the ocular findings and management in a case of thyroid eye disease (Graves' Ophthalmopathy [GO]) following alemtuzumab therapy. The ocular disease was managed conservatively while the systemic Graves' was managed with thyroidectomy.
阿仑单抗（Campath-1H）是一种人源化抗CD52单克隆抗体，用于治疗多发性硬化症（MS）。研究表明，使用该药物后复发风险和累积持续性残疾的风险显著降低。不良事件包括输液相关反应、感染和继发性自身免疫。系统性甲状腺疾病是最常见的继发性自身免疫事件，约30%的接受治疗患者会受到影响。本文首次描述了阿仑单抗治疗后甲状腺眼病（格雷夫斯眼病[GO]）的眼部表现及处理情况。眼部疾病采用保守治疗，而系统性格雷夫斯病则通过甲状腺切除术进行治疗。
